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Abstract
The structural basis of the quaternary organization of rhodopsin has recently been explored and modeled. Because information
obtained from studying rhodopsin has frequently been directly applicable to other G protein-coupled receptors we wished to ascertain if
dimeric and/or oligomeric forms of the 1b-adrenoceptor could be observed and if so whether rhodopsin might provide insights into the
quaternary structure of this receptor. Co-immunoprecipitation and both conventional and time-resolved Xuorescence resonance energy
transfer studies demonstrated quaternary structure of the 1b-adrenoceptor and, in concert with the reconstitution of fragments of this
receptor, provided information on the molecular basis of these interactions. Development of three color Xuorescence resonance energy
transfer (FRET) allowed the imaging of 1b-adrenoceptor oligomers in single living cells. Mutation of hydrophobic residues in transmem-
brane domains I and IV of the receptor resulted in marked reduction in three color FRET suggesting an alteration in oligomeric organi-
zation and potential similarities with rhodopsin. The mutated 1b-adrenoceptor was unable to reach the cell surface, did not become
terminally N-glycosylated and was unable to signal.
© 2006 Elsevier Ltd. All rights reserved.
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Recent evidence has indicated that most G protein-
coupled receptors (GPCRs)1 do not generally exist as
monomers but rather as dimers or, potentially, within
higher-order oligomers (Milligan, 2004a). Support for such
models has been provided by a range of studies employing
diVerent approaches, including co-operativity of ligand
binding, co-immunoprecipitation of co-expressed but
diVerentially epitope-tagged forms of the same GPCR and
a variety of resonance energy transfer techniques (Milligan
& Bouvier, 2005; PXeger & Eidne, 2006). However, only for
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1 Abbreviations used: CFP, cyan Xuorescent protein; FRET, Xuorescence
resonance energy transfer; GFP, green Xuorescent protein; GPCR, G pro-
tein-coupled receptor; YFP, yellow Xuorescent protein.0042-6989/$ - see front matter © 2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.visres.2006.08.007a few GPCRs has information on the molecular basis of
quaternary interactions become available and only for rho-
dopsin has the organizational structure of a GPCR been
imaged in situ. Because many aspects of the function and
structure of rhodopsin have proved to have direct parallels
in other GPCRs, this information has impacted on our
studies on the 1b-adrenoceptor.
2. The structural organization of rhodopsin
High resolution, three-dimensional crystal structures
of a GPCR are only available for rhodopsin (Li,
Edwards, Burghammer, Villa, & Schertler, 2004; Palczew-
ski et al., 2000). However, these static structures of deter-
gent-extracted receptor, although remarkably
informative on the orientation and organization of the
seven transmembrane helix bundle, provided no insights
into potential quaternary structure. By contrast, both the
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mouse rod outer segments (Liang et al., 2003) and the use
of cryo-electron microscopy on two-dimensional crystals
of squid rhodopsin (Davies, Gowen, Krebs, Schertler, &
Saibil, 2001) have shown higher-order organization of the
protein. In the pictures obtained by atomic force micros-
copy, rhodopsin is organized within para-crystalline
arrays with densely packed, double rows of the receptor.
Using such images as a starting point, and given the high
density of rhodopsin in rod outer segments, models of
potential quaternary structure were generated that
optimized packing arrangements. These models suggested
interactions between rows of dimers to be provided by
contacts between elements of transmembrane domain I,
whilst key interactions between monomers of a dimer
appear to be provided by contacts involving transmem-
brane domains IV and V (Fotiadis et al., 2004). Interest-
ingly, the electron density maps derived from the two-
dimensional crystals of squid rhodopsin provide evidence
of a symmetrical transmembrane domain IV–transmem-
brane domain IV interaction as a key structural interface
(Davies et al., 2001) and although squid rhodopsin has
relatively low overall sequence identity with mammalian
opsins this may well represent a conserved element in
interactions between rhodopsin-like, family A GPCRs.
As an alternative approach to explore the basis of pro-
tein–protein interactions, opsin was recently expressed
heterologously in COS1 cells (Kota, Reeves, Rajbhan-
dary, & Khorana, 2006). Following initial Xuorescence
resonance energy transfer (FRET) experiments to con-
Wrm interactions between forms of opsin tagged with
either cyan or yellow Xuorescent protein, dimer forma-
tion was assessed by the rate of disulphide bond forma-
tion in the presence of cupric ortho-phenanthroline, using
opsin mutants in which a range of speciWc amino acids
were mutated to cysteine. These studies showed most
rapid dimer formation with the mutants W175C (trans-
membrane domain IV) and Y206C (transmembrane
domain V) (Kota et al., 2006) consistent with key roles of
these regions in quaternary structure. Of course, the rod
outer segment is a highly specialized structure in which
rhodopsin comprises close to 50% of the total protein. By
contrast, many GPCRs in other tissues are expressed in
relatively small amounts. It is therefore unclear if the
in situ oligomeric organization of rhodopsin is relevant
to other GPCRs or to other environments. Recently,
however, molecules of rhodopsin reconstituted into aso-
lectin liposomes were shown to self-associate into dimers
or multimers (Mansoor, Palczewski, & Farrens, 2006)
and this provided evidence that rhodopsin can spontane-
ously self-associate in membranes other than the rod
outer segment (Mansoor et al., 2006). Furthermore,
recent studies on the molecular basis of dimerization of
the dopamine D2 receptor has provided clear evidence
for a key role of transmembrane domain IV (Guo, Shi, &
Javitch, 2003; Guo, Shi, Filizola, Weinstein, & Javitch,
2005).3. The 1-adrenoceptors
The 1-adrenoceptor family in man and other mammals
is derived from three related genes. These encode the
1a-, 1b- and 1d-adrenoceptor subtypes (Piascik & Perez,
2001). Although ligands with substantial discrimination
between the subtypes have been relatively slow to emerge,
recent advances in this area, combined with gene knockout
technologies, have indicated overlap of distribution and
key functions of these GPCRs in regulating vascular tone
and hypertrophic growth of smooth muscle and cardiac
cells (Koshimizu, Tanoue, Hirasawa, Yamauchi, & Tsujim-
oto, 2003).
3.1. 1b-Adrenoceptor dimerization: Initial studies
Initial studies on the structural organization of the 1b-
adrenoceptor used co-immunoprecipitation of diVerently
epitope-tagged forms of the receptor. Only when the two
forms were co-expressed in heterologous cells and not
when diVerent cell populations, each expressing one form
of the receptor, were mixed prior to immunoprecipitation
with antibody to one of the two epitope tags, was co-
immunoprecipitation achieved (Carrillo, Pediani, & Milli-
gan, 2003; Stanasila, Perez, Vogel, & Cotecchia, 2003;
Uberti, Hall, & Minneman, 2003). In each of these cases,
following SDS–PAGE of the immunoprecipitated sam-
ples and immunoblotting to detect the tag not used for
immunoprecipitation, a series of bands were detected. The
polypeptide with highest mobility corresponded to the
expected size for an 1b-adrenoceptor monomer. Bands
with lesser mobility were approximately twice the size of
the monomer, whilst a further, less well deWned group of
immunoreactive bands entered the gels poorly. Although
there may be exceptions (Zeng & Wess, 1999), interactions
between rhodopsin-family GPCRs are not generally
anticipated to involve covalent links. It thus remains pos-
sible that the polypeptides with apparent high molecular
mass are simply protein aggregates stemming from
removal of the receptors from the membrane lipid envi-
ronment. In the studies of Carrillo et al. (2003) and Sta-
nasila et al. (2003), further approaches were employed to
support the co-immunoprecipitation data. Stanasila et al.
(2003) C-terminally tagged the 1b-adrenoceptor with
either cyan Xuorescent protein (CFP) or green Xuorescent
protein (GFP) and employed FRET to demonstrate prox-
imity and hence potential interactions when the two forms
were co-expressed. They also demonstrated that addi-
tional expression of 1b-adrenoceptor not tagged with a
Xuorescent protein reduced the FRET signal and that
such a reduction in FRET signal was not produced by co-
expressing the CCR5 chemokine receptor, a GPCR that is
only distantly related to the 1b-adrenoceptor. Carrillo
et al. (2003) employed a distinct FRET-based technique.
Taking advantage of the N-terminal epitope tags intro-
duced for the co-immunoprecipitation studies, they
employed time-resolved FRET between anti-epitope tag
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acceptor species and hence demonstrated interactions
between successfully cell surface-delivered forms of the
1b-adrenoceptor in intact cells. Carrillo et al. (2003) also
developed a functional complementation strategy. They
had previously shown that a single open-reading frame
fusion protein between the 1b-adrenoceptor and the 
subunit of the Ca2+ mobilizing G protein G11 was func-
tional and could be used to measure agonist stimulated
binding of [35S]GTPS (Carrillo, Stevens, & Milligan,
2002). Now they demonstrated that the ability of the
fusion protein to bind [35S]GTPS in an agonist-depen-
dent manner could be eliminated by either a point muta-
tion in the second intracellular loop of the receptor or by
a point mutation in the G protein. When the two inacti-
vated fusion proteins were co-expressed, agonist-mediated
binding of [35S]GTPS was restored. Because this also
occurred in cells that lack endogenous expression of any
Ca2+ mobilizing G proteins, it must have involved an
inter-molecular interaction between the two inactive
fusion proteins. Carrillo, Lopez-Gimenez, and Milligan
(2004) subsequently conWrmed the capacity of C-termi-
nally CFP and yellow Xuorescent protein (YFP)-tagged
forms of the 1b-adrenoceptor to generate FRET signals
following co-expression.
3.2. How does the 1b-adrenoceptor dimerize?
As a Wrst approach to this question Stanasila et al.
(2003) generated a series of mutated and modiWed forms
of the receptor. Studies on the yeast  factor receptor had
identiWed a glycophorin A-like motif (GXXXG) in trans-
membrane helix I and shown that modiWcation of key
amino acids of this motif resulted in a reduction in FRET
consistent with abrogation of dimerization (Overton, Chi-
nault, & Blumer, 2003). Although the 1b-adrenoceptor
has a similar motif in transmembrane helix I, the muta-
tion Gly53Leu in this region did not reduce FRET signals
(Stanasila et al., 2003). Neither did an equivalent muta-
tion of a second glycophorin A-like motif in transmem-
brane helix VI. A variety of studies had suggested roles
for both the intracellular C-terminal tail and the glycosyl-
ation state of the extracellular N-terminal region in pro-
tein–protein interactions of other rhodopsin-like GPCRs
(Milligan, 2004a). However, neither truncation of the C-
terminal tail nor mutation to prevent N-glycosylation
reduced FRET signals of the 1b-adrenoceptor. Indeed, C-
terminal truncation actually resulted in a higher FRET
signal (Stanasila et al., 2003). However, as FRET signals
are dependent upon both distance between, and the rela-
tive orientation of, the FRET donor and acceptor (Milli-
gan, 2004b), interpretation of this observation is diYcult.
Based on demonstration of an interaction between the full
length 1b-adrenoceptor and a fragment comprising only
the N-terminal extracellular domain and transmembrane
domain I by time-resolved FRET, Carrillo et al. (2003,
2004) adopted a systematic receptor fragment-interactionapproach. This involved taking the extracellular N-termi-
nus of the 1b-adrenoceptor and linking it to fragments of
the receptor consisting of transmembrane domains, I, III,
V or VII and, because of the anti-parallel arrangement of
the intervening domains, transmembrane domains I + II,
III + IV and V + VI that also incorporated the intracellu-
lar loops that link these pairs of transmembrane domains.
Each of these constructs was then used in every possible
combination for both co-immunoprecipitation and time-
resolved FRET studies to identify interactions. Only
transmembrane domain I and transmembrane domain IV
displayed symmetrical interactions, i.e. they self-associ-
ated. These results were potentially consistent with the
1b-adrenoceptor forming dimers in two distinct ways, via
transmembrane domain I–I interactions and via trans-
membrane domain IV–IV interactions (Fig. 1). Interest-
ingly, both of these regions have received support as
dimerization interfaces in studies employing diVerent
GPCRs (Milligan, 2005). However, comparisons with the
atomic force microscope images of the in situ organiza-
tion of rhodopsin (Fotiadis et al., 2004; Liang et al., 2003)
suggested the possibility of a more complex model.
Viewed from the extracellular space, the transmembrane
helices of GPCRs are organized in an anti-clockwise ori-
entation. Transmembrane domain I–transmembrane
domain I interactions between adjacent monomers leaves
transmembrane domain IV available to form a IV–IV
interaction which then leaves transmembrane domain I
free to potentially generate a further interaction. This pat-
tern could build up into a ‘daisy-chain’ of repeating
dimers to generate an oligomer of undeWned size (Fig. 1).
Furthermore, the receptor fragment complementation
studies also indicated a series of non-symmetrical interac-
tions involving elements of transmembrane domains I
and/or II with transmembrane domains V and/or VI and
it was hypothesized that such interactions could allow
rows of dimers to form (Carrillo et al., 2004).
Stanasila et al. (2003) had shown a lack of substantial
FRET signal following co-expression of 1b-adrenoceptor-
CFP and 2-adrenoceptor-GFP, suggesting that these two
closely related GPCRs do not interact. To identify
transmembrane domains responsible for 1b-adrenoceptor
self-interactions they thus generated forms of the 1b-adre-
noceptor in which each transmembrane domain was sys-
tematically replaced with the corresponding sequence from
the 2-adrenoceptor. Statistically signiWcant decreases in
FRET signal were reported only with replacement of
transmembrane domain I and transmembrane domain VII.
By contrast, FRET signals were absent when the full
length 1b-adrenoceptor was co-expressed with fragments
of the receptor that lacked the N-terminus and transmem-
brane domains I + II, although not when a fragment com-
prising the N-terminus and the sequence up to and
including transmembrane domain III was co-expressed
(Stanasila et al., 2003). Thus, although these studies did not
provide evidence for a key role of transmembrane domain
IV, they did imply a role for transmembrane domain I.
G. Milligan et al. / Vision Research 46 (2006) 4434–4441 4437Fig. 1. Models of the organization of the 1b-adrenoceptor. Models of the quaternary structure of the 1b-adrenoceptor are based on the anti-clockwise
orientation of transmembrane domains I–VII of individual GPCR polypeptides as viewed from the extracellular space. Data from co-immunoprecipita-
tion and time-resolved FRET studies performed using fragments of the 1b-adrenoceptor indicate symmetrical transmembrane domain I-transmembrane
domain I interactions and transmembrane domain IV–transmembrane domain IV interactions. These observations are compatible with two distinct ways
of forming 1b-adrenoceptor dimers (A and B). However, data also indicate that the 1b-adrenoceptor can exist as a higher-order oligomer. One way that
this may be achieved, that is consistent with both models A and B, is shown in C (See the text and Carrillo et al., 2004 for further details).
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430 nm when Y67C YFP is employed must therefore represent direct CFP to dsRED2 and the diVerence in FRET signal when employing YFP rather than
Y67C YFP therefore represents the ‘sequential’ three color signal that can report on oligomeric organization of the 1b-adrenoceptor (see text for further
details). (For interpretation of the references in color in this Wgure legend, the reader is referred to the web version of this article.)
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Two component FRET cannot usefully discriminate
between dimers and higher-order structures. Lopez-Gime-
nez, Canals, Pediani, and Milligan (2006) therefore devel-
oped and employed a sequential three color FRET imaging
approach to gain support for oligomeric structures of the
1b-adrenoceptor in single living cells that might be similar
to the observed organization of rhodopsin in rod outer seg-
ment discs. Initially, these studies employed a single open-
reading frame concatamer of CFP, YFP and DsRed2, as
initially used by others (Galperin, Verkhusha, & Sorkin,
2004) to establish appropriate imaging conditions. Follow-
ing transfection of this concatamer into HEK293 cells, Xuo-
rescence corresponding to each of CFP, YFP and DsRed2
could be observed in single cells and with appropriate exci-
tation, and the application of a novel FRET algorithm,
each of CFP to YFP, YFP to DsRed2 and CFP to DsRed2
FRET could be measured in single cells. To prove that the
CFP to DsRed2 FRET signal truly represented sequential
CFP to YFP to DsRed2 energy transfer and not direct CFP
to DsRed2 FRET, a second concatamer was employed.
This was identical to the Wrst except it contained a Tyr67Cys
mutation in the YFP element. This mutation ablatesXuorescence of YFP and therefore Tyr67Cys YFP can act as
neither a resonance energy transfer donor nor acceptor.
CFP to DsRed2 FRET was abolished, conWrming the CFP
to DsRed2 FRET produced from the initial concatamer
represented sequential CFP to YFP to DsRed2 FRET and
not direct CFP to DsRed2 FRET (Fig. 2).
With this information in place, forms of the 1b-adreno-
ceptor C-terminally tagged with each of CFP, YFP and
DsRed2 were co-expressed in HEK293 cells and produced
CFP to DsRed2 FRET. Such observations are consistent
with at least a proportion of the 1b-adrenoceptor existing
in an oligomeric complex (Lopez-Gimenez et al., 2006). By
contrast, simple co-expression of each of CFP, YFP
and DsRed2 produced no such FRET signal. Equally
co-expression of 1b-adrenoceptor-CFP, 1b-adrenoceptor-
Tyr67CysYFP and 1b-adrenoceptor-DsRed2 failed to gen-
erate CFP to DsRed2 FRET (Lopez-Gimenez et al., 2006).
3.4. Disruption of eVective oligomerization prevents cell 
surface delivery of the 1b-adrenoceptor
To explore the role of transmembrane domains I and IV
in oligomerization, pairs of adjacent, hydrophobic residues
in these regions (Fig. 3) were mutated to alanines and threeFig. 3. Mutations introduced into the 1b-adrenoceptor to attempt to modulate oligomeric organization. The 1b-adrenoceptor is displayed in a ribbon
diagram as a monomeric polypeptide. Based, in part, on the bio-informatic analysis of (de Juan et al., 2005) hydrophobic amino acids at the locations
noted in transmembrane domains I and IV were mutated to alanines. These amino acids are coded using the nomenclature of Ballesteros and Weinstein
that relates positions in the transmembrane domains to the location of the most conserved residue in that helix.
L1.52A
V1.53A
L4.47A
L4.46A
NH2
COOH
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reduced sequential three color FRET consistent with alter-
ations in the oligomeric interactions and organization of
the receptor (Lopez-Gimenez et al., 2006). The functional
consequences of this were also explored. Immunocyto-
chemistry to detect an N-terminal epitope tag demon-
strated wild type 1b-adrenoceptor at the cell surface.
However, cell surface expression of the mutant 1b-adreno-
ceptor could not be detected although, following cell per-
meabilization, it was clear that the mutant was expressed as
eVectively as the wild type receptor. Good expression of the
mutated form could also be shown by simply monitoring
Xuorescence of cells expressing C-terminally YFP-tagged
forms of the wild type and mutated 1b-adrenoceptor
(Lopez-Gimenez et al., 2006).
Following transfection into a range of cell types
(Morris, Price, Smith, Lei, & Schwinn, 2004; Pediani et al.,
2005) and in physiological settings (Mackenzie, Daly,
Pediani, & McGrath, 2000) wild type 1-adrenoceptors
recycle between the cell surface and endosomal compart-
ments in a constitutive, agonist-independent manner. This
can be shown using an anti-epitope tagged antibody
labeled with the pH-sensitive dye CypHer-5 if the receptor
is appropriately N-terminally tagged (Adie et al., 2003).
CypHer-5 displays red Xuorescence only when in an acidic
environment, such as an endosome, and addition of the
labeled antibody to cells expressing a suitably tagged
1b-adrenoceptor resulted in the development of redXuorescence without addition of an agonist ligand. This is
consistent with the receptor moving from the cell surface
into an endosomal pool in a ligand-independent manner.
By contrast, for many other GPCRs, including the orexin-
1 receptor, this only occurs in the presence of agonist
(Milasta et al., 2005). A number of other GPCRs, includ-
ing the cannabinoid CB1 receptor (Leterrier, Bonnard,
Carrel, Rossier, & Lenkei, 2004; Leterrier et al., 2006),
share the characteristic of spontaneous internalization
with 1-adrenoceptors. Whilst addition of receptor antag-
onists restricts the spontaneous recycling of most of these
GPCRs, this is not so for the 1-adrenoceptors. Indeed,
1-adrenoceptors are able to bind cell-impermeable antag-
onists whilst at the cell surface and carry these into the
cell as the receptor cycles. BODIPY-labeled variants of
antagonists related to the prototypic 1-adrenoceptor
blocker prazosin display Xuorescence only when bound to
the receptor (Pediani et al., 2005). They can therefore be
used to monitor whether an 1-adrenoceptor had previ-
ously been at the cell surface. When a BODIPY-labeled
antagonist, that displays red Xuorescence when bound to
receptor, was added to cells expressing a C-terminally
YFP-tagged form of the 1b-adrenoceptor, the cells devel-
oped red Xuorescence in punctuate intracellular vesicles
(Fig. 4). Pixel by pixel analysis demonstrated strong yel-
low/red color overlap (Fig. 4), indicating that the antago-
nist remained associated with the receptor inside the cell.
This was not observed in cells expressing the mutatedFig. 4. The wild type 1b-adrenoceptor but not Leu
65Ala, Val66Ala, Leu166Ala, Leu167Ala 1b-adrenoceptor is able to reach the cell surface. HEK293 cells
were transfected to express FLAG-tagged forms of wild type 1b-adrenoceptor-YFP (A) or Leu
65Ala, Val66Ala, Leu166Ala, Leu167Ala 1b-adrenoceptor-
YFP (B). Cells were treated with Hoeschst nuclear stain and Red QAPB for 30 min and imaged; A1, B1 YFP; A2, B2 Hoeschst; A3, B3 Red QAPB; A4, B4
merged images. The ability of the wild type 1b-adrenoceptor to bind Red QAPB is a demonstration that only this form of the receptor was successfully
delivered to the cell surface.
A1 A3 A4A2
B1 B3 B4B2
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receptor had not been delivered to the plasma membrane
(Fig. 4).
To explore a possible basis for the lack of cell surface
delivery of the mutated 1b-adrenoceptor, studies were per-
formed to examine receptor N-glycosylation. Although the
wild type receptor was present as both apparent 75 and
105kDa polypeptides, no 105 kDa form of the mutant was
observed. De-glycosylation studies demonstrated the
105kDa form of the wild type receptor to represent the
mature form of the protein. Following treatment with N-gly-
cosidase F this band was absent and the wild type receptor
now migrated with apparent Mr close to 70 kDa (Lopez-
Gimenez et al., 2006). The mutant receptor thus appeared to
be unable to become terminally N-glycosylated. An inability
to be terminally N-glycosylated often is associated with poor
plasma membrane delivery and traYcking of mutants of a
range of GPCRs which are then sent to the proteasome for
destruction (Petaja-Repo et al., 2001).
3.5. The mutated 1b-adrenoceptor is unable to signal
As the mutated 1b-adrenoceptor appeared unable to
reach the cell surface then it was expected to be unable to
signal in response to agonist ligands. This was conWrmed in
HEK293 cells expressing either the wild type 1b-adreno-
ceptor, C-terminally tagged with YFP or the mutant recep-
tor C-terminally tagged with CFP. Such cells were grown
on the same cover slip, loaded with the ratiometric Ca2+
indicator dye FURA-2 and exposed to the 1-adrenoceptor
agonist phenylephrine. Increases in intracellular Ca2+ were
only observed in cells expressing the wild type receptor
(Lopez-Gimenez et al., 2006). This was not a reXection that
cells expressing the mutated 1b-adrenoceptor were unable
to respond to receptor ligands. Subsequent to washout of
the 1-adrenoceptor agonist, ATP was added to activate
P2Y purinoceptors that are expressed endogenously by
HEK293 cells. Equivalent increases in intracellular Ca2+
were now observed in all cells.
4. Conclusions
As with many aspects of GPCR structure, function and
regulation, understanding of the structural organization of
rhodopsin in rod outer segments has greatly inXuenced ideas
about other members of the rhodopsin-like GPCR family.
Although a range of studies have indicated that the 1b-adre-
noceptor possesses quaternary structure, it had been unclear
if this was restricted solely to the formation of dimers or
whether higher-order complexes might exist. Application of
sequential three color FRET imaging in concert with frag-
ment complementation approaches have help to deWne pro-
tein–protein interaction interfaces for the 1b-adrenoceptor
and indicate similarities in overall organization with
rhodopsin. However, these studies have relied on heterolo-
gous expression of the 1b-adrenoceptor and it will be impor-
tant to develop means to assess if 1b-adrenoceptoroligomerization can also be observed in native tissues. It
remains to be established whether oligomerization will be a
general feature of other family A GPCRs and whether the
molecular contacts involved will also be highly conserved.
Although it appears that rhodopsin may retain function
when limited to be a monomer, one role for oligomerization
of the 1b-adrenoceptor appears to be to ensure cell surface
delivery and hence a means to bind and response to circulat-
ing norepinephrine and epinephrine.
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